Brands
Farah Khan and Sufi Motiwala add a festive twist to fashion in Myntra’s Iftar campaign
MUMBAI: Myntra has unveiled its latest campaign, Jashn-e-Iftar, turning a fashion duel into a festive extravaganza. The campaign stars film choreographer Farah Khan and fashion critic Sufi Motiwala in a lively qawwali showdown, bringing together humour, style, and the spirit of celebration.
Set against the backdrop of an elegant Iftar gathering, the film opens with Sufi taking the stage, dishing out his signature sharp-witted fashion critiques. Just as he delivers his verdict, Farah steps in, playfully countering him with her own qawwali-style verses. What begins as a battle of wits soon transforms into a joyful celebration of personal style, highlighting the fun and freedom of festive dressing.
Myntra director of brand & digital marketing Abhishek Gour shared, “Festivals are all about expressing yourself with confidence, and this campaign captures that essence perfectly. With our extensive range of ethnic wear, luxury gifts, and home décor, we make it easy for everyone to embrace the festive spirit in style.”
Farah added, “Festivals bring people together, and what better way to celebrate than with fashion and fun? This campaign perfectly captures the joy of dressing up, making a statement, and creating memories.”
Sufi remarked, “Fashion is meant to be expressive and bold. This campaign flips the script on my usual critiques, making it a playful and entertaining celebration of personal style. Working with Farah was an absolute delight.”
The creative minds at toaster India brought the campaign to life, with chief creative officer Ira G describing the concept as a beautiful blend of banter and tradition.
The campaign showcases Myntra’s curated selection of ethnic fashion, luxurious gifting options, and elegant home décor, making it the go-to destination for festive shopping this season.
Brands
Sun Pharma to acquire Organon in $11.75 billion deal at $14 per share
Acquisition to create $12.4 billion pharma giant with global scale and biosimilars push
MUMBAI: Sun Pharmaceutical Industries Limited has signed a definitive agreement to acquire Organon & Co. in an all-cash deal valued at $11.75 billion, marking one of the largest cross-border pharma acquisitions by an Indian firm.
Under the terms of the agreement, Organon shareholders will receive $14.00 per share in cash, with Sun Pharma set to acquire 100 per cent of the company’s outstanding shares. The transaction, approved by the boards of both companies, is expected to close in early 2027, subject to regulatory approvals and shareholder consent.
The deal significantly expands Sun Pharma’s global footprint and strengthens its position across women’s health, biosimilars, and branded generics. The combined entity is projected to generate revenues of around $12.4 billion, placing it among the top 25 pharmaceutical companies globally.
Organon, which was spun off from Merck in 2021, brings a portfolio of over 70 products spanning women’s health and general medicines, with operations across more than 140 countries. Its established presence in key markets such as the US, Europe, and China complements Sun Pharma’s existing strengths and growth ambitions.
Sun Pharmaceutical Industries Limited executive chairman Dilip Shanghvi said, “This transaction represents a significant opportunity for Sun Pharma to build on its vision of reaching people and touching lives. Organon’s portfolio, capabilities and global reach are highly complementary to our own.”
Sun Pharmaceutical Industries Limited managing director Kirti Ganorkar added, “This transaction is a logical next step in strengthening Sun Pharma’s global business. Together, we will become a partner of choice for acquiring and launching new products.”
From Organon’s side, Organon & Co. executive chair Carrie Cox noted, “This all-cash transaction offers compelling and immediate value to Organon stockholders, while positioning the business for continued growth under Sun Pharma.”
Strategically, the acquisition gives Sun Pharma entry into the global biosimilars space as a top 10 player and strengthens its innovative medicines portfolio, which is expected to contribute around 27 per cent of combined revenues. The deal is also expected to nearly double EBITDA and cash flow, supporting long-term deleveraging and investment capacity.
Sun Pharma plans to fund the acquisition through a mix of internal accruals and committed financing from global banks, while maintaining focus on disciplined integration and operational continuity post-merger.
If completed as planned, the deal signals a clear shift in India’s pharmaceutical ambitions, from scale at home to leadership on the global stage, with Sun Pharma positioning itself as a more diversified and innovation-led healthcare powerhouse.
